This raises the possibility that MUC1-C may act as an upstream regulator coordinating these two responses.154,339 As a consequence of this coordination, researchers have hypothesized that patients with mesenchymal tumors are more likely to benefit from immunotherapy, particularly for anti-PD-L1 or PD-1-neutralizing antibodies against PD-L1 overexpression.122 The possible role of PD-L1 as a prognostic factor in patients undergoing PD-1/PD-L1 inhibitor treatment is still under investigation and needs further studies and testing in clinical practice. The gene discussed is PDCD1; the disease is mesenchymal cell neoplasm.